Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04863248
Title Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors G1 Therapeutics, Inc.
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Trilaciclib

Docetaxel

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST